Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianweixiaoyan Granules is a Traditional Chinese Medicine (TCM) product developed and manufactured by Shanxi Buchang Pharmaceutical. It is primarily indicated for the treatment of digestive system disorders, including chronic gastritis, gastric ulcers, and duodenal ulcers, particularly those associated with the TCM syndrome of "damp-heat" in the spleen and stomach. The formulation is composed of several botanical extracts, including *Taraxacum mongolicum* (Dandelion), *Scutellaria baicalensis* (Chinese Skullcap), *Poria cocos*, *Atractylodes macrocephala*, and *Corydalis yanhusuo*, which collectively provide anti-inflammatory, analgesic, and gastric mucosal protective effects. The drug is approved in China and is widely used to alleviate symptoms such as epigastric pain, abdominal distension, and acid regurgitation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jianweixiaoyan granules.